Biotech

Search documents
What Makes Amgen (AMGN) a New Buy Stock
ZACKS· 2025-07-15 17:01
Core Viewpoint - Amgen (AMGN) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][2]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of changing earnings estimates, which are strongly correlated with near-term stock price movements [3][5]. - Institutional investors often rely on earnings estimates to determine a company's fair value, leading to significant stock price movements based on these estimates [3]. Amgen's Earnings Outlook - For the fiscal year ending December 2025, Amgen is expected to earn $20.85 per share, which remains unchanged from the previous year [7]. - Over the past three months, the Zacks Consensus Estimate for Amgen has increased by 1.2%, reflecting a positive trend in earnings estimates [7]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [6]. - The upgrade of Amgen to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9].
NanoViricides positioned at forefront of Mpox treatment efforts, says Zacks
Proactiveinvestors NA· 2025-07-15 16:29
About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...
Nasdaq Gains Over 100 Points; Wells Fargo Earnings Top Views
Benzinga· 2025-07-15 16:06
U.S. stocks traded mixed midway through trading, with the Nasdaq gaining more than 100 points on Tuesday.The Dow traded down 0.57% to 44,204.33 while the NASDAQ gained 0.71% to 20,786.86. The S&P 500 also rose, gaining, 0.01% to 6,269.15.Check This Out: How To Earn $500 A Month From Morgan Stanley Stock Ahead Of Q2 EarningsLeading and Lagging SectorsInformation technology shares jumped by 1.6% on Tuesday.In trading on Tuesday, materials stocks dipped by 0.9%.Top HeadlineWells Fargo & Company WFC reported be ...
Wall Street Analysts Think Exact Sciences (EXAS) Could Surge 26.24%: Read This Before Placing a Bet
ZACKS· 2025-07-15 14:56
Exact Sciences (EXAS) closed the last trading session at $54.3, gaining 1.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $68.55 indicates a 26.2% upside potential.The average comprises 22 short-term price targets ranging from a low of $54.00 to a high of $90.00, with a standard deviation of $7.85. While the lowest estimate indicates a decline of 0.6% from the current price leve ...
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
ZACKS· 2025-07-15 14:41
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors rely on traditional forms of analysis on key valuation metrics to fi ...
Faruqi & Faruqi Reminds Sarepta Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 - SRPT
Prnewswire· 2025-07-15 14:34
Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sarepta Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the safety of its drug ELEVIDYS [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Sarepta between June 22, 2023, and June 24, 2025, to discuss their legal rights [1]. - There is an August 25, 2025, deadline for investors to seek the role of lead plaintiff in a federal securities class action against Sarepta [2]. - The complaint alleges that Sarepta and its executives made false statements regarding the safety of ELEVIDYS, which posed significant risks to patients [4]. Group 2: Stock Price Impact - Following a safety update on March 18, 2025, Sarepta's stock price fell by $27.81 per share, or 27.44%, closing at $73.54 [5]. - On April 4, 2025, after disclosing regulatory scrutiny, the stock price dropped by $4.18 per share, or 7.13%, closing at $54.43 [6]. - A second patient death reported on June 15, 2025, led to a significant stock price decline of $15.24 per share, or 42.12%, closing at $20.91 [8]. - Following an FDA Safety Communication on June 24, 2025, the stock price fell by $1.52 per share, or 8.01%, closing at $17.46 [9]. Group 3: Company Background - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in multiple states [3].
Tempus AI Raises 2025 Financial Outlook: What's Backing It?
ZACKS· 2025-07-15 14:20
Key Takeaways Tempus AI now expects 2025 revenues of $1.25B and adjusted EBITDA of $5M, both raised from prior guidance. TEM's Q1 sales surged 75.4% and gross profit nearly doubled on lab gains and a higher data services mix. TEM's deals with AstraZeneca and Pathos and hereditary testing growth from Ambry Genetics drove guidance hike.Tempus AI (TEM) expects full-year 2025 revenues of $1.25 billion (up from the previous $1.24 billion guidance), which represents approximately 80% annual growth. The company ...
Lisata Therapeutics expands IP with key patent covering certepetide's chemical structure and uses
Proactiveinvestors NA· 2025-07-15 13:33
About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...
X @Bloomberg
Bloomberg· 2025-07-15 12:46
Sino Biopharmaceutical says it will take over the privately held Chinese biotech company LaNova Medicines https://t.co/2cfh2Kwp0r ...
IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan
Globenewswire· 2025-07-15 12:05
Core Points - IMUNON, Inc. has received approval from the Nasdaq Hearing Panel for an exception to complete its compliance plan, allowing the company to maintain its Nasdaq listing [1][2] - The Nasdaq Hearing Panel noted that IMUNON has achieved compliance with the Equity Rule through recent fundraising activities and will implement a compliance plan to meet minimum shareholder equity and bid price requirements [2][3] - The Panel approved a tailored exception for IMUNON to regain compliance within a designated timeframe, rather than the full 180 days initially requested [3] Company Overview - IMUNON is a clinical-stage biotechnology company focused on developing innovative treatments that utilize the body's natural mechanisms to generate effective responses against various diseases [5] - The company is advancing its non-viral DNA technology, with its lead clinical program, IMNN-001, being a DNA-based immunotherapy for advanced ovarian cancer [6] - IMNN-001 has completed multiple clinical trials, including a Phase 2 trial, and the company has also conducted a first-in-human study for its COVID-19 booster vaccine, IMNN-101 [6]